Table 2.
Competing risk regression (CRR) model of hypothyroidism risk at >0 months, >3 months, and >6 months of monotherapya
| p‐value | Beta coefficient | Standard error | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Covariate | >0 | >3 | >6 | >0 | >3 | >6 | >0 | >3 | >6 |
| Treatment (Wald) | 3.86E‐03 | 6.22E‐03 | 3.61E‐03 | – | – | – | – | – | – |
| Aripiprazole | 7.39E‐03 | 8.80E‐03 | 2.44E‐03 | −2.37E‐01 | −3.63E‐01 | −5.98E‐01 | 8.85E‐02 | 1.39E‐01 | 1.97E‐01 |
| Carbamazepine | 1.35E‐01 | 6.14E‐02 | 2.20E‐02 | −2.76E‐01 | −6.18E‐01 | −1.34E+00 | 1.85E‐01 | 3.30E‐01 | 5.85E‐01 |
| Lamotrigine | 1.47E‐03 | 2.53E‐02 | 3.48E‐02 | −2.27E‐01 | −2.26E‐01 | −2.70E‐01 | 7.12E‐02 | 1.01E‐01 | 1.28E‐01 |
| Olanzapine | 1.11E‐02 | 5.15E‐02 | 2.47E‐02 | −3.24E‐01 | −4.02E‐01 | −6.84E‐01 | 1.27E‐01 | 2.06E‐01 | 3.05E‐01 |
| Oxcarbazepine | 1.51E‐02 | 2.21E‐01 | 4.50E‐01 | −3.41E‐01 | −2.42E‐01 | −1.79E‐01 | 1.40E‐01 | 1.97E‐01 | 2.37E‐01 |
| Quetiapine | 4.16E‐01 | 5.06E‐01 | 8.51E‐01 | −6.36E‐02 | 7.45E‐02 | 2.68E‐02 | 7.82E‐02 | 1.12E‐01 | 1.43E‐01 |
| Risperidone | 5.90E‐03 | 3.88E‐01 | 6.34E‐01 | −3.19E‐01 | −1.48E‐01 | −1.06E‐01 | 1.16E‐01 | 1.71E‐01 | 2.22E‐01 |
| Valproate | 8.96E‐03 | 3.08E‐01 | 4.41E‐01 | −2.32E‐01 | −1.29E‐01 | −1.25E‐01 | 8.88E‐02 | 1.27E‐01 | 1.62E‐01 |
| Age at exposure | 6.91E‐10 | 2.14E‐05 | 1.12E‐04 | 1.12E‐02 | 1.10E‐02 | 1.32E‐02 | 1.81E‐03 | 2.59E‐03 | 3.41E‐03 |
| Sex, male | 3.93E‐07 | 9.79E‐05 | 2.28E‐05 | −2.65E‐01 | −2.93E‐01 | −4.11E‐01 | 5.23E‐02 | 7.53E‐02 | 9.70E‐02 |
| Pre‐Tx thyroidism | 6.37E‐06 | 8.50E‐02 | 6.71E‐01 | 4.68E‐01 | 2.80E‐01 | 9.73E‐02 | 1.04E‐01 | 1.63E‐01 | 2.29E‐01 |
| Post‐Tx thyroid tests rank | 2.79E‐87 | 3.25E‐53 | 3.65E‐30 | 2.88E+00 | 3.13E+00 | 2.84E+00 | 1.46E‐01 | 2.04E‐01 | 2.49E‐01 |
| Pre‐Tx thyroid tests 14 days | 2.69E‐07 | 2.74E‐03 | 9.58E‐03 | −4.16E‐01 | −4.05E‐01 | −5.06E‐01 | 8.09E‐02 | 1.35E‐01 | 1.95E‐01 |
Tx = treatment.
a
The final model includes six variables, with treatment coded as eight dummy variables with lithium as reference. The three treatment variable p‐values are the result of Wald tests that calculate the significance of the eight dummy variables combined. Results are contrasted with subcohorts on >3 and >6 months of monotherapy.